Latest News

Beyond Tolvaptan: The Next Generation of ADPKD Therapies

Beyond Tolvaptan: The Next Generation of ADPKD Therapies

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and the leading monogenic cause of kidney failure worldwide, affecting an estimated 12.5 million people globally. For nearly a decade, tolvaptan — a vasopressin V2...

read more

Latest News

NAMs and Animal Testing: Separating Progress From Hype

NAMs and Animal Testing: Separating Progress From Hype

If you followed the headlines over the past two years, you could be forgiven for thinking animal testing in drug development is already on its way out. In December 2022, the FDA Modernization Act 2.0 removed the blanket legal requirement for animal studies to support...

read more
Clinical Trials Roundup | 17 July 2026

Clinical Trials Roundup | 17 July 2026

Celcuity's gedatolisib receives FDA approval as the first pan-PI3K and mTOR inhibitor for advanced breast cancer, Biogen's diranersen delivers detailed Phase 2 CELIA data showing tau reduction and cognitive benefit in early Alzheimer's disease, Novo Nordisk's...

read more
Biopharma H1 2026 Review: Deals, Drugs, and Pipeline Shifts

Biopharma H1 2026 Review: Deals, Drugs, and Pipeline Shifts

The first half of 2026 delivered one of the most consequential periods in recent biopharma history, reshaping competitive landscapes through record dealmaking, landmark regulatory approvals, and pivotal clinical breakthroughs. This biopharma H1 2026 review examines...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Power Outages as a Clinical Risk Multiplier in Healthcare

Power Outages as a Clinical Risk Multiplier in Healthcare

Electricity as a Hidden Dependency in Healthcare Reliable electricity is a foundational requirement for modern healthcare systems. From acute hospital care to long-term residential facilities and home-based treatment, uninterrupted power underpins virtually every...

read more
The Physician Gap That’s Slowing Life Sciences

The Physician Gap That’s Slowing Life Sciences

We work with hospitals, clinics, and health systems across the country every day. Over the past few years, one thing has become very clear: filling a specialist role is harder than it used to be, it takes longer, and the consequences of getting it wrong reach further...

read more
Protecting R&D and Clinical Trial Data in the Age of AI

Protecting R&D and Clinical Trial Data in the Age of AI

Drug development is one of the most expensive and time-intensive innovation processes in the world. Estimates from the Tufts Center for the Study of Drug Development suggest that bringing a new drug to market can cost over $2.6 billion and take more than a decade of...

read more
Medical Writers Become Strategic Partners

Medical Writers Become Strategic Partners

In regulated drug development, documentation shapes how a program is understood long before regulators ever see it. Protocols, investigator brochures, integrated summaries, and submission-ready modules establish the scientific and strategic narrative of a development...

read more
Weekly News Roundup | 16 March 2026

Weekly News Roundup | 16 March 2026

Your essential life science news digest: the past week's biggest stories in pharma, biotech and healthcare. 👇 This week's life science news was defined by regulatory uncertainty and clinical momentum. A landmark FDA leadership departure sent rare disease stocks...

read more
Reflections and Healing at the End of Life

Reflections and Healing at the End of Life

Words To Begin At age 81, the author has lived a "life of letters" (perhaps three million words) addressing a wide variety of subjects during multiple careers: Systems Engineering (PhD at UCLA in 1976), Military Science (21 years on active duty, in high-tech...

read more
Power Outages as a Clinical Risk Multiplier in Healthcare

Power Outages as a Clinical Risk Multiplier in Healthcare

Electricity as a Hidden Dependency in Healthcare Reliable electricity is a foundational requirement for modern healthcare systems. From acute hospital care to long-term residential facilities and home-based treatment, uninterrupted power underpins virtually every...

read more
The Physician Gap That’s Slowing Life Sciences

The Physician Gap That’s Slowing Life Sciences

We work with hospitals, clinics, and health systems across the country every day. Over the past few years, one thing has become very clear: filling a specialist role is harder than it used to be, it takes longer, and the consequences of getting it wrong reach further...

read more
Protecting R&D and Clinical Trial Data in the Age of AI

Protecting R&D and Clinical Trial Data in the Age of AI

Drug development is one of the most expensive and time-intensive innovation processes in the world. Estimates from the Tufts Center for the Study of Drug Development suggest that bringing a new drug to market can cost over $2.6 billion and take more than a decade of...

read more
Medical Writers Become Strategic Partners

Medical Writers Become Strategic Partners

In regulated drug development, documentation shapes how a program is understood long before regulators ever see it. Protocols, investigator brochures, integrated summaries, and submission-ready modules establish the scientific and strategic narrative of a development...

read more
Weekly News Roundup | 16 March 2026

Weekly News Roundup | 16 March 2026

Your essential life science news digest: the past week's biggest stories in pharma, biotech and healthcare. 👇 This week's life science news was defined by regulatory uncertainty and clinical momentum. A landmark FDA leadership departure sent rare disease stocks...

read more
Reflections and Healing at the End of Life

Reflections and Healing at the End of Life

Words To Begin At age 81, the author has lived a "life of letters" (perhaps three million words) addressing a wide variety of subjects during multiple careers: Systems Engineering (PhD at UCLA in 1976), Military Science (21 years on active duty, in high-tech...

read more

Featured Articles

FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 31 July 2026. Covering target action dates from August to December 2026. The closing stretch of the third quarter has become the busiest regulatory window of 2026. Between early August and the end of September, the US Food and Drug Administration faces...
Pipette dispensing into lab vials with glowing DNA helix and genetic sequence data for Life Science Daily News

Life Science Daily News: Eight Months of Growth and a Global Community Taking Shape

Life Science Daily News launched in November 2025 with a simple premise: that researchers, biotech founders, healthcare professionals, communications specialists and industry professionals should be able to publish their own work directly to a specialist audience,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

The Microbiome: The Missing Layer in Modern Metabolic Care

The Microbiome: The Missing Layer in Modern Metabolic Care

Over the last decade, obesity management has undergone a structural transformation. What was once a field dominated almost exclusively by bariatric surgery has evolved into a far more nuanced metabolic discipline. The rise of GLP-1 receptor agonists and dual incretin...

read more
FDA Overhauls Pharmacokinetic Study Requirements

FDA Overhauls Pharmacokinetic Study Requirements

FDA Overhauls Pharmacokinetic Study Requirements in New Biosimilar Draft Guidance The US Food and Drug Administration (FDA) has overhauled biosimilar pharmacokinetic study requirements in new draft guidance issued on 9 March 2026, aimed at further reducing the time...

read more
Breakthroughs in the Lab – Blind Spots in Reality 

Breakthroughs in the Lab – Blind Spots in Reality 

Obesity care is at a turning point. GLP-1s like Ozempic and Mounjaro have upended weight loss culture – and the research backs them up. For the first time, multiple randomized trials have found that anti-obesity medications can lead to an average 15-20% weight loss....

read more

Further News

Will Artificial Intelligence Replace Medical Science Liaisons?

What Global Surveys of Medical Affairs Professionals Reveal Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, prompting many Medical Affairs professionals to ask whether some roles may eventually become obsolete. Headlines regularly...

GLP-1 Uptake by Country: Where Ozempic and Mounjaro are Booming in 2026

The global market for glucagon-like peptide-1 (GLP-1) receptor agonists has entered a new phase. What began as a breakthrough in type 2 diabetes management has become one of the defining pharmaceutical stories of the decade. In 2025, the GLP-1 receptor agonist market...

AI’s Next Leap in Biopharma: From Acceleration to Intelligence in Partnership

Artificial intelligence has already changed the rhythm of discovery in biopharma. Algorithms can screen millions of molecules, identify trial candidates, and forecast supply chains with extraordinary speed. Yet speed is not the same as progress. The next chapter of AI...

Weekly News Roundup | 15 June 2026

Life science news 15 June 2026: GSK's $10.6 billion Nuvalent acquisition headlines a blockbuster M&A week, the MHRA approves the UK's first oral weight-loss semaglutide tablet, and the FDA clears a new adjuvant combination for kidney cancer in a landmark week for...

What GLP-1 Patients Don’t Know About Muscle Loss and Why It Matters

GLP-1 receptor agonists are transforming obesity treatment. But the clinical conversation about lean muscle preservation is lagging behind the prescribing rate, and that gap has real consequences for patients, says Omar el-Gohary. There is a version of the GLP-1...

Why Europe’s Precision Oncology Trials Keep Stalling

Precision medicine works when the right biomarker test reaches the right patient in time. In Europe, the regulatory plumbing is making that harder than it should be. At the 16th Clinical Biomarkers & CDx Summit in London in March 2026, I discussed lessons from MDx...

Complement Inhibitor Setback: Sanofi Halts CIDP Study

Sanofi has halted a late-stage trial of its experimental complement inhibitor riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), a setback that analysts say could create volatility across the wider complement inhibitor field. The company said in...

Clinical Trials Roundup | 12 June 2026

Survodutide delivers dual Phase 3 success in obesity and metabolic liver disease at ADA 2026, secukinumab becomes the first targeted biologic to demonstrate sustained remission in polymyalgia rheumatica, dapirolizumab pegol meets its Phase 3 primary endpoint in...

Foundayo vs Rybelsus: The Oral GLP-1 Guide for 2026

The oral GLP-1 market has changed faster in the past six months than in the previous six years. Where once Rybelsus stood alone as the only GLP-1 pill available, patients and clinicians must now navigate three distinct oral products, each with a different molecule, a...

The Case for Agility: Why Biopharma Must Embrace Adaptive Trial Designs

For decades, the landscape of clinical research was dominated by fixed, traditional trial designs. In these legacy studies, the primary objective was often maintaining a strict, unchanging protocol from inception to conclusion. But the landscape of modern medicine has...

GSK’s $10.6 Billion Nuvalent Deal: Reshaping the Lung Cancer Drug Race

Two FDA decision dates, 18 September and 27 November, are now the most important dates on GSK's calendar. On 9 June 2026, the British pharmaceutical giant announced it had agreed to acquire Cambridge, Massachusetts-based Nuvalent for $10.6 billion in cash, securing...

FDA Drug Approval Decisions: June and July 2026

The summer months at the United States Food and Drug Administration are typically among the busiest on the regulatory calendar, and 2026 is proving no exception. With a succession of high-profile FDA drug approval decisions concentrated in June and July 2026, the...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.